While a direct link between JNK activation and the anti-tumor mechanisms of either ixazomib or dinaciclib remains largely unexplored, several studies have reported the ability of these drugs to potentiate chemotherapy-associated JNK signaling. The gene discussed is MAPK8; the disease is neoplasm.